瑞银发表研究报告指,药明康德(02359.HK) 去年第四季收入按年增长9.2%至126亿元人民币(下同),股东应占纯利按年增长151.8%至74亿元,收入符合初步业绩,纯利则略高于预期。去年持续经营业务收入按年增长21.4%,经调整毛利率按年提升6.6个百分点至48.2%。截至去年底,持续经营业务在手订单达580亿元,按年增长28.8%。按业务划分,化学业务收入按年增长25.5%至365亿元,...
Source Link瑞银发表研究报告指,药明康德(02359.HK) 去年第四季收入按年增长9.2%至126亿元人民币(下同),股东应占纯利按年增长151.8%至74亿元,收入符合初步业绩,纯利则略高于预期。去年持续经营业务收入按年增长21.4%,经调整毛利率按年提升6.6个百分点至48.2%。截至去年底,持续经营业务在手订单达580亿元,按年增长28.8%。按业务划分,化学业务收入按年增长25.5%至365亿元,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.